Latest Investor Confidence News

SkyCity Entertainment Group has resolved a decade-long dispute over casino duty calculations with South Australia’s Treasurer, agreeing to a $38.1 million settlement that ends ongoing legal proceedings.

Simble Solutions Limited has raised $280,000 through a premium-priced equity placement, signaling renewed investor confidence in its sustainability software platforms.

Ten Sixty Four Limited reports a 9% rise in gold production to 13,123 ounces and a reduction in all-in-sustaining costs to US$2,045 per ounce for the September 2024 quarter, while advancing its Tigerway Decline project and navigating ongoing restructuring.

Kalium Lakes Limited reports progress on its recapitalisation plan following operational setbacks and administration, while shares remain suspended on the ASX.

Pure Foods Tasmania reports improved revenue and gross profit margin for 2Q25, driven by aggressive cost-cutting and operational efficiencies, while continuing negotiations to lift its ASX trading suspension.

Jindalee Lithium Limited reported a $935,000 net cash outflow for the December 2024 quarter, maintaining a cautious but confident stance on securing future funding to support ongoing exploration activities.

RooLife Group (ASX: RLG) reported a striking 144% increase in sales revenue for Q2 FY2025, driven by the launch of new online stores across China, Hong Kong, Australia, and India. The company is investing heavily in product development and marketing to capitalize on booming health and wellness markets.

Epsilon Healthcare's December 2023 quarterly report reveals significant boardroom conflict and governance breaches, yet operational segments show promising growth.

Tombador Iron Limited reported a modest net cash outflow of $317,000 for the December 2024 quarter, yet holds robust cash reserves of $10.825 million, underpinning over 34 quarters of operational funding.

Alchemy Resources Limited reported a slight $15,000 cash outflow in its December 2024 quarter, maintaining a solid cash balance of $2 million as it continues to invest in exploration activities.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

iCandy Interactive reports a remarkable 105% increase in net cash flow for Q4 2024 despite a 22% drop in cash receipts, driven by strategic expansions and operational efficiencies amid ongoing legal disputes.